RenovoRx Executes Definitive Subscription Agreement With Accredited Investors For $11.1M At Market Private Placement
RenovoRx Executes Definitive Subscription Agreement With Accredited Investors For $11.1M At Market Private Placement
RenovorX通过市场私募与合格投资者签署了1110万美元的最终认购协议
- Cash position now expected to fund current operating plan into 2026
- Financing provides cash runway to advance the ongoing pivotal Phase III TIGeR-PaC trial through the second interim readout and towards completion of the trial
- Financing also enables the expansion of RenovoRx's TAMP (Trans-Arterial Micro-Perfusion) clinical development pipeline into additional cancer indications
- 现在预计现金状况将为2026年的当前运营计划提供资金
- 融资为将正在进行的关键的Tiger-Pac第三阶段试验推进到第二次中期读数和完成试验提供了现金渠道
- 融资还使RenovorX的TAMP（经动脉微灌注）临床开发管道扩展到其他癌症适应症